CSTL vs. CELC, FLGT, VRDN, HHLA, NVTA, BDSX, VCYT, RNA, PETQ, and EHAB
Should you be buying Castle Biosciences stock or one of its competitors? The main competitors of Castle Biosciences include Celcuity (CELC), Fulgent Genetics (FLGT), Viridian Therapeutics (VRDN), HH&L Acquisition (HHLA), Invitae (NVTA), Biodesix (BDSX), Veracyte (VCYT), Avidity Biosciences (RNA), PetIQ (PETQ), and Enhabit (EHAB). These companies are all part of the "medical" sector.
Celcuity (NASDAQ:CELC) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, community ranking, risk, analyst recommendations, institutional ownership, valuation and earnings.
In the previous week, Castle Biosciences had 6 more articles in the media than Celcuity. MarketBeat recorded 8 mentions for Castle Biosciences and 2 mentions for Celcuity. Celcuity's average media sentiment score of -1.11 beat Castle Biosciences' score of -1.90 indicating that Castle Biosciences is being referred to more favorably in the news media.
Celcuity has a net margin of 0.00% compared to Celcuity's net margin of -39.32%. Celcuity's return on equity of -19.50% beat Castle Biosciences' return on equity.
Celcuity has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Castle Biosciences has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.
63.3% of Celcuity shares are held by institutional investors. Comparatively, 85.8% of Castle Biosciences shares are held by institutional investors. 24.3% of Celcuity shares are held by insiders. Comparatively, 7.7% of Castle Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Celcuity has higher earnings, but lower revenue than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks.
Celcuity received 241 more outperform votes than Castle Biosciences when rated by MarketBeat users. Likewise, 66.25% of users gave Celcuity an outperform vote while only 61.11% of users gave Castle Biosciences an outperform vote.
Celcuity presently has a consensus target price of $25.00, indicating a potential upside of 67.22%. Castle Biosciences has a consensus target price of $32.29, indicating a potential upside of 60.07%. Given Castle Biosciences' higher probable upside, equities research analysts clearly believe Celcuity is more favorable than Castle Biosciences.
Summary
Celcuity and Castle Biosciences tied by winning 8 of the 16 factors compared between the two stocks.
Get Castle Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Castle Biosciences Competitors List
Related Companies and Tools